ARVINAS, INC. Debt Securities, Available-for-sale, Realized Gain (Loss)
ARVINAS, INC. (ARVN) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2026-02-24
- ARVINAS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-12-31 was $0.00.
- ARVINAS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-09-30 was $0.00.
- ARVINAS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-06-30 was $0.00.
- ARVINAS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-03-31 was $0.00.
- ARVINAS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2025 was $0.00.
- ARVINAS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2024 was $0.00.
- ARVINAS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2023 was -$900.00K.
- ARVINAS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2022 was -$400.00K.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $0.00 derived: sum of 2 quarters · filed 2024-10-30 | $0.00 10-Q · filed 2024-10-30 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $0.00 10-Q · filed 2024-07-30 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | -$900.00K 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $0.00 derived: sum of 2 quarters · filed 2024-10-30 | -$900.00K 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | -$900.00K 10-Q · filed 2024-07-30 | ||
| 2023-03-31 | -$900.00K 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$400.00K 10-K · filed 2025-02-11 | |||
| 2021-12-31 | -$200.00K 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $400.00K 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |